Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Margaret C. Minkwitz"'
Autor:
Phillip E. Korenblat, Margaret C. Minkwitz, James P. Kemp, William Mezzanotte, Joseph E. Scherger
Publikováno v:
Annals of Allergy, Asthma & Immunology. 84:217-225
Background The Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT), evaluated zafirlukast in a wide spectrum of patients from a variety of clinical practices. Objective To determine the effect of age on the response to zafirlukast 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d072405a199c1479856db33f406bc237
https://doi.org/10.1016/s1081-1206(10)62759-7
https://doi.org/10.1016/s1081-1206(10)62759-7
Publikováno v:
Chest. 115:336-342
We evaluated the efficacy of the leukotriene receptor antagonist zafirlukast (Accolate), 20 mg twice daily, as monotherapy in patients with severe persistent asthma (defined by an FEV160% of predicted before treatment and frequent night-time symptoms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814d94c0197e2eb21453a8faa4701862
https://doi.org/10.1378/chest.115.2.336
https://doi.org/10.1378/chest.115.2.336
Autor:
Michael J. Watts, Stephen C. Lazarus, Hofer Wong, Margaret C. Minkwitz, Bernard J. Lavins, Homer A. Boushey
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 156:1725-1730
Inhalation of sulfur dioxide (SO2) causes bronchoconstriction in most people with asthma. To examine the role of leukotrienes in this response, the antagonism of SO2-induced bronchoconstriction by a single oral dose of the leukotriene receptor antago
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74cad71a50da5bb09770205ae4d8aec
https://doi.org/10.1164/ajrccm.156.6.9608006
https://doi.org/10.1164/ajrccm.156.6.9608006
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 82(5)
New drug evaluations in patients with mild asthma are sometimes complicated by enrollment of patients whose disease is too mild to show improvement with therapy. A peak expiratory flow (PEF) variability criterion may help to more clearly define a mil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd5d5fb9527169dd5b42ef5bc11269e
https://pubmed.ncbi.nlm.nih.gov/10875496
https://pubmed.ncbi.nlm.nih.gov/10875496
Autor:
Catherine M. Bonuccelli, Robert A. Nathan, Steven G. Simonson, Donald P. Tashkin, William C. Howland, Margaret C. Minkwitz
Publikováno v:
The Journal of allergy and clinical immunology. 103(2 Pt 1)
Consensus asthma guidelines recommend antileukotriene agents as alternative therapy to existing anti-inflammatory medications; however, the full therapeutic potential of these medications has not yet been determined.The purpose of this study was to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d22b5a9a7ca3e40e035f6ec1ebca8fe
https://pubmed.ncbi.nlm.nih.gov/9949315
https://pubmed.ncbi.nlm.nih.gov/9949315
Autor:
Robert L. Wortmann, Ralph H. Schumacher, William A. Palo, Nancy Joseph-Ridge, Michael A. Becker, Patricia A. McDonald, Daniel Flores, Roderick J. Halbert, Jeannine Guenther, Kate Zhong, Pierre N. Tarcot, Margaret C. Minkwitz, Nancy A. Devine, Jacobo Mintzer
Publikováno v:
The Consultant Pharmacist. 21:76-77
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3034a7ce193c6a1eacd572797ffeb708
https://doi.org/10.4140/tcp.n.2006.76
https://doi.org/10.4140/tcp.n.2006.76
Publikováno v:
Chest. 105(2)
Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges. Each subject received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0bcba9687181971ac8a514102df17d8
https://pubmed.ncbi.nlm.nih.gov/8306751
https://pubmed.ncbi.nlm.nih.gov/8306751
Publikováno v:
Clinical pharmacology and therapeutics. 54(4)
The peptide-leukotriene antagonist, ICI 204,219 [4-(5-cyclopentyloxycarbonylamino-lmethylindol-3-ylmethyl)-3-methoxy-n-o-tolylsulfonyl benzamide], was administered 12 hours before an inhaled leukotriene D4 (LTD4) challenge during a double-blind, plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6e33fbcb4c5204c4088fc1122a6ef53
https://pubmed.ncbi.nlm.nih.gov/8222486
https://pubmed.ncbi.nlm.nih.gov/8222486